FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910139063> ?p ?o ?g. }

• W2910139063 endingPage "3633" @default.
• W2910139063 startingPage "3633" @default.
• W2910139063 abstract "Abstract Background The hemoglobin (Hb) response to the activin receptor type IIA ligand trap ACE-011 (Sotatercept) in non-transfusion-dependent thalassemia (NTDT), and the transfusion requirement response in TDT are described, but the mechanisms of action, clinical predictors and markers of response, are unclear. In principle, ACE-011 may act on early and/or late erythroblasts to decrease ineffective erythropoiesis (IE), both in healthy subjects and in thalassemia. As erythropoiesis intimately links to iron metabolism, changes in markers of iron metabolism relative to those of erythropoiesis may inform the mechanisms and developmental stage at which ACE-011 acts. Methods Markers of IE and iron metabolism in 46 thalassemia patients (30 NTDT, 16 TDT) were taken before and during a median follow up of 722.5 days, (IQR 830.5, range 152-1427) of escalating doses of ACE-011 (3-weekly 0.1 to 1.0 mg/kg s.c. injections), depending on the protocol, as part of the approved study (Cappellini, et al. 2018 under review). Markers of erythropoiesis included Hb, Reticulocytes (Ret), soluble transferrin receptor 1 (sTfR), growth differentiation factor 11 and 15 (GDF11, GDF15), erythroferrone (ERFE). Markers of iron metabolism included plasma hepcidin, serum ferritin (SF), transferrin saturation (TSAT), and non-transferrin-bound iron (NTBI). Data were analyzed using longitudinal multilevel model for change (LMMC) on STATA (Version 14) as generalized linear mixed model with random and fixed effects to account for repeated measures and highly complex temporal data structure. Final LMMCs were built to explain the change in Hb from baseline and the behavior of key biomarkers. Independent variables were entered into the models based on the study design (predictors from design) and theoretical background (predictors of interest and control variables). P value <0.05 was considered statistically significant. Results Predictors of response. In NTDT, Hb response associated positively with dose and duration of exposure (both at p<0.0001), and negatively with baseline EPO (p=0.002), GDF15 (p<0.0001) or TSAT. In TDT, accounting for transfusion effect, baseline GDF15 and EPO positively predicted Hb response while ERFE was a negative predictor (all at p<0.0001). Biomarker changes with time In NTDT, significant changes with time on study were increases in Hb, sTfR, ERFE and Ret and decreases in hepcidin, bilirubin, and NTBI. GDF15 showed no change. In TDT, GDF15, sTfR and ERFE increased, whereas hepcidin decreased. The Hb change was insignificant in TDT (as expected per protocol) and was dose-independent, however the mean 41% reduction in transfusion iron load rate (ILR) was dose dependent, implying an equivalent net production of Hb in TDT (Table 1). Other significant relationships Absolute hepcidin level in NTDT and TDT was negatively predicted by ERFE (p<0.0001): the first longitudinal demonstration of this association in thalassemia patients. GDF11, the target for ACE-011 that was shown previously to negatively regulate erythroid differentiation (Dussiot et al, Nat Med 2014), fell significantly on study (preliminary data). Significant reduction in indirect bilirubin in NTDT, implying reduced hemolysis, suggests improved quality of produced erythrocytes. Interpretation and conclusions NTDT patients allow a cleaner interpretation of biomarker changes as these are confounded in TDT by increased bone marrow stress from less transfusion. In NTDT, sTfR and ERFE (total erythropoiesis) increase on study while GDF15 (IE) and EPO do not. Thus Hb gain may result from increased effectiveness of late stage erythropoiesis (sTfR+ and ERFE+) possibly from decreased apoptosis and more rapid maturation (Carrancio et al, BJH 2014) in this compartment. We speculate that increased survival of those erythroid progenitor cells expressing TfR (and hence sTfR) and ERFE (hence increased ERFE) also explains the observed hepcidin reduction. Despite exposure to lower hepcidin, there is no iron loading: NTBI falls against stable SF in NTDT, consistent with shunting of iron into the sink of effective erythropoiesis. The reduction in GDF11 in vivo, not previously reported for ACE-011, is also consistent with increased apoptosis of the early progenitor pool and with improved erythroblast differentiation relative to proliferation as suggested in murine β-thalassemia treated with ACE-011 (Dussiot, et al. Nat Med 2014). Disclosures Garbowski: Vifor: Consultancy. Hermine:Erythec: Research Funding; AB Science: Consultancy, Equity Ownership, Honoraria, Research Funding; Celgene Corporation: Research Funding; Hybrigenics: Research Funding; Novartis: Research Funding. Cappellini:Sanofi/Genzyme: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria; Vifor: Membership on an entity's Board of Directors or advisory committees; Celgene Corporation: Membership on an entity's Board of Directors or advisory committees. Origa:Bluebird Bio: Consultancy; Novartis: Honoraria; Cerus Corporation: Research Funding; Apopharma: Honoraria. Forni:Celgene: Research Funding; Novartis: Other: travel expenses, Research Funding; Shire: Research Funding; Roche: Consultancy; Apopharma: Other: DSM Board. Voskaridou:Acceleron: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene Corp: Membership on an entity's Board of Directors or advisory committees, Research Funding. Galactéros:Addmedica: Other: grant; Novartis: Other: grant. Taher:Novartis: Consultancy, Honoraria, Research Funding; La Jolla Pharmaceutical: Research Funding; Protagonist Therapeutics: Consultancy; Celgene Corp.: Research Funding; Ionis Pharmaceuticals: Consultancy. Ribeil:bluebird bio: Consultancy; Vitalaire: Other: grant; Addmedica: Other: grant; Cydan: Consultancy; Novartis: Consultancy. Laadem:Celgene: Employment, Equity Ownership. Miteva:Celgene Corporation: Employment, Other: grants. Zou:Celgene Corporation: Employment, Equity Ownership. Zinger:Celgene Corporation: Employment. Schwickart:Celgene Corporation: Employment, Equity Ownership. Sung:Celgene Corporation: Employment, Equity Ownership. Porter:Novartis: Consultancy; Cerus: Honoraria; Agios: Honoraria." @default.
• W2910139063 created "2019-01-25" @default.
• W2910139063 creator A5003992164 @default.
• W2910139063 creator A5007098177 @default.
• W2910139063 creator A5009338104 @default.
• W2910139063 creator A5013341235 @default.
• W2910139063 creator A5015705263 @default.
• W2910139063 creator A5016689216 @default.
• W2910139063 creator A5017005000 @default.
• W2910139063 creator A5018110033 @default.
• W2910139063 creator A5020535984 @default.
• W2910139063 creator A5020947734 @default.
• W2910139063 creator A5031440349 @default.
• W2910139063 creator A5032057695 @default.
• W2910139063 creator A5049244658 @default.
• W2910139063 creator A5058078318 @default.
• W2910139063 creator A5062525225 @default.
• W2910139063 creator A5064118994 @default.
• W2910139063 creator A5064856085 @default.
• W2910139063 creator A5067176684 @default.
• W2910139063 creator A5072237761 @default.
• W2910139063 creator A5077415507 @default.
• W2910139063 creator A5084870748 @default.
• W2910139063 date "2018-11-29" @default.
• W2910139063 modified "2023-10-18" @default.
• W2910139063 title "GDF15 and Erythroferrone Mark Erythropoietic Response to ACE-011 (Sotatercept) in Thalassemia" @default.
• W2910139063 doi "https://doi.org/10.1182/blood-2018-99-111770" @default.
• W2910139063 hasPublicationYear "2018" @default.
• W2910139063 type Work @default.
• W2910139063 sameAs 2910139063 @default.
• W2910139063 citedByCount "0" @default.
• W2910139063 crossrefType "journal-article" @default.
• W2910139063 hasAuthorship W2910139063A5003992164 @default.
• W2910139063 hasAuthorship W2910139063A5007098177 @default.
• W2910139063 hasAuthorship W2910139063A5009338104 @default.
• W2910139063 hasAuthorship W2910139063A5013341235 @default.
• W2910139063 hasAuthorship W2910139063A5015705263 @default.
• W2910139063 hasAuthorship W2910139063A5016689216 @default.
• W2910139063 hasAuthorship W2910139063A5017005000 @default.
• W2910139063 hasAuthorship W2910139063A5018110033 @default.
• W2910139063 hasAuthorship W2910139063A5020535984 @default.
• W2910139063 hasAuthorship W2910139063A5020947734 @default.
• W2910139063 hasAuthorship W2910139063A5031440349 @default.
• W2910139063 hasAuthorship W2910139063A5032057695 @default.
• W2910139063 hasAuthorship W2910139063A5049244658 @default.
• W2910139063 hasAuthorship W2910139063A5058078318 @default.
• W2910139063 hasAuthorship W2910139063A5062525225 @default.
• W2910139063 hasAuthorship W2910139063A5064118994 @default.
• W2910139063 hasAuthorship W2910139063A5064856085 @default.
• W2910139063 hasAuthorship W2910139063A5067176684 @default.
• W2910139063 hasAuthorship W2910139063A5072237761 @default.
• W2910139063 hasAuthorship W2910139063A5077415507 @default.
• W2910139063 hasAuthorship W2910139063A5084870748 @default.
• W2910139063 hasBestOaLocation W29101390631 @default.
• W2910139063 hasConcept C126322002 @default.
• W2910139063 hasConcept C134018914 @default.
• W2910139063 hasConcept C136935669 @default.
• W2910139063 hasConcept C153852466 @default.
• W2910139063 hasConcept C203014093 @default.
• W2910139063 hasConcept C22814914 @default.
• W2910139063 hasConcept C2776485076 @default.
• W2910139063 hasConcept C2776768029 @default.
• W2910139063 hasConcept C2777417653 @default.
• W2910139063 hasConcept C2777799968 @default.
• W2910139063 hasConcept C2778248108 @default.
• W2910139063 hasConcept C2778319317 @default.
• W2910139063 hasConcept C2779703530 @default.
• W2910139063 hasConcept C2780844101 @default.
• W2910139063 hasConcept C3019673199 @default.
• W2910139063 hasConcept C32264632 @default.
• W2910139063 hasConcept C71924100 @default.
• W2910139063 hasConceptScore W2910139063C126322002 @default.
• W2910139063 hasConceptScore W2910139063C134018914 @default.
• W2910139063 hasConceptScore W2910139063C136935669 @default.
• W2910139063 hasConceptScore W2910139063C153852466 @default.
• W2910139063 hasConceptScore W2910139063C203014093 @default.
• W2910139063 hasConceptScore W2910139063C22814914 @default.
• W2910139063 hasConceptScore W2910139063C2776485076 @default.
• W2910139063 hasConceptScore W2910139063C2776768029 @default.
• W2910139063 hasConceptScore W2910139063C2777417653 @default.
• W2910139063 hasConceptScore W2910139063C2777799968 @default.
• W2910139063 hasConceptScore W2910139063C2778248108 @default.
• W2910139063 hasConceptScore W2910139063C2778319317 @default.
• W2910139063 hasConceptScore W2910139063C2779703530 @default.
• W2910139063 hasConceptScore W2910139063C2780844101 @default.
• W2910139063 hasConceptScore W2910139063C3019673199 @default.
• W2910139063 hasConceptScore W2910139063C32264632 @default.
• W2910139063 hasConceptScore W2910139063C71924100 @default.
• W2910139063 hasIssue "Supplement 1" @default.
• W2910139063 hasLocation W29101390631 @default.
• W2910139063 hasOpenAccess W2910139063 @default.
• W2910139063 hasPrimaryLocation W29101390631 @default.
• W2910139063 hasRelatedWork W1860194906 @default.
• W2910139063 hasRelatedWork W1971778304 @default.
• W2910139063 hasRelatedWork W1982996857 @default.
• W2910139063 hasRelatedWork W2051875442 @default.
• W2910139063 hasRelatedWork W2118046222 @default.
• W2910139063 hasRelatedWork W2416716871 @default.

• next